Program Overview
This CME/CE program will highlight the application of poly (ADP-ribose) polymerase (PARP) inhibitors to improve outcomes for patients with advanced ovarian cancer. The expert faculty, led by Dr. Don Dizon, will first review updates to the National Comprehensive Care Network (NCCN) evidence-based guidelines. Next, an analysis of current and emerging clinical trial data of PARP Inhibitors will be discussed. Following, the faculty will assess how to collaborate with the multi-disciplinary team for optimal treatment and management of adverse effects associated with PARP inhibitors. The faculty will conclude with a panel discussion, delving further into healthcare disparities, share decision making, and how to better manage patients with advanced ovarian cancer.
Target Audience
Gynecologic oncologists, medical oncologists, pathologists, advanced practice providers, and other members of the multi-disciplinary care team who care for patients with advanced ovarian cancer.
Agenda
I. A Review of Updates to NCCN Evidence-based Guidelines in Advanced Ovarian Cancer – Don Dizon, MD
II. A Scientific Analysis and Clinical Trial Review of PARP Inhibitors for the Treatment of Patients with Advanced Ovarian Cancer – Shannon MacLaughlan, MD
III. Patient Education and the Mitigation of Adverse Effects – Christine McGinn, NP
IV. Round Table Discussion – All Faculty
a. Shared Decision Making
b. Healthcare Disparities
Learning Objectives
- Review and analyze updates to NCCN evidence-based guidelines in advanced ovarian cancer
- Examine the rationale for use of PARP inhibitors in maintenance treatment settings for advanced ovarian cancer
- Collaborate with the multi-disciplinary team for optimal treatment selection and management of treatment-related adverse effects associated with PARP inhibitors
- Effectively support patient education, shared decision-making with the inter-professional team, and addressing healthcare disparities for patients with advanced ovarian cancer
Faculty
Don S. Dizon, MD
Director, The Pelvic Malignancies Program and Hematology/Oncology Outpatient Clinics, LCI
Director, Medical Oncology and the Oncology Sexual Health Program, RI Hospital
Professor of Medicine, Brown University
Head, Community Outreach and Engagement, The Cancer Center at Brown University
Providence, RI
Shannon MacLaughlan, MD
Associate Professor
Obstetrics & Gynecology
Division Director, Gynecologic Oncology
UIC Cancer Center
Chicago, IL
Christine McGinn, NP
Rhode Island Hospital
Providence, RI
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Don S. Dizon, MD | Independent Data Monitoring Committee: AstraZeneca; Clovis; GSK |
| Shannon MacLaughlan, MD | Nothing to disclose |
| Christine McGinn, NP | Nothing to disclose |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider number P0491).
Financial Support
This activity has been supported by an independent educational grant from GSK
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and GSK do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
